Comparative efficacy, safety, and acceptability of single-agent poly (ADP-ribose) polymerase (PARP) inhibitors in BRCA-mutated HER2-negative metastatic or advanced breast cancer: a network meta-analysis

Background: Breast cancer is the most commonly diagnosed cancer and is the leading cause of cancer death in women worldwide. Both talazoparib and olaparib are approved by the US Food and Drug Administration for treating BRCA (breast cancer 1, early onset)-mutated HER2 (human epidermal growth factor...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Ju, Zhang, Ye, Yuan, Long, Ren, Lin, Zhang, Yi, Qi, Xiaowei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals 2020
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7834995/
https://www.ncbi.nlm.nih.gov/pubmed/33257598
http://dx.doi.org/10.18632/aging.202152

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7834995/
https://www.ncbi.nlm.nih.gov/pubmed/33257598
http://dx.doi.org/10.18632/aging.202152

Ejemplares similares